Hyperthermic Antiblastic Perfusion in the Treatment of Loco-Regional Spreading Limb Melanoma

Journal of Experimental and Clinical Cancer Research

Volumn 22, Issue 4 SUPPL., 2003, Pages 89-95

  Di Filippo, Franco ^a   Garinei, R ^a   Giannarelli, D ^a   Anza M ^a   Cavaliere, F ^a   Botti, C ^a   Perri, P ^a   Di Filippo, S ^a   Psaila, A ^a   Callopoli, A ^a   Maialetti, R ^a   Sega, F ^a   Frezza, F ^a   Viticci, C ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hyperthermic antiblastic perfusion; Limb melanoma; Prognostic factors

Indexed keywords

MELPHALAN;

ADJUVANT CHEMOTHERAPY; ARTERY OCCLUSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; EDEMA; ERYTHEMA; HUMAN; HYPERTHERMIA; HYPERTHERMIC ANTIBLASTIC PERFUSION; INTERMETHOD COMPARISON; LIMB MELANOMA; LIMB PAIN; LIMB TUMOR; MAJOR CLINICAL STUDY; MELANOMA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TEMPERATURE MEASUREMENT; THROMBOPHLEBITIS; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EXTREMITIES; HUMANS; HYPERTHERMIA, INDUCED; MELANOMA; MELPHALAN; SURVIVAL ANALYSIS;

EID: 12144287742     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. WHO Collaborating Centers of Evaluation of Methods of Diagnosis and Treatment of Melanoma: Metastatic spread of stage I melanoma of the skin. Tumori 69:449-545, 1983.
2. Lee Y.T.: Loco-regional recurrent melanoma. II. Nonsystemic treatments (1964-1979). Cancer Treat. Rev. 15:105-33, 1988.
3. Einhom L.H., McBride C.M., Luce J.K., et al.: Intra-arterial infusion therapy with 5 (3.3 Dimethyl-Triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma. Cancer 32:749-55, 1973.
4. Oberfield R.A., Sullivan R.D.: Prolonged and continuous regional arterial infusion chemotherapy in patients with melanoma. J.A.M.A. 209:75-9, 1969.
5. Pritchard J.D., Mavligit G.M., Benjamin R.S.: Regression of regionally confined melanoma with intraarterial cis-dichloro-diammine platinum. Cancer Treat. Rep. 63:555-8, 1979.
6. Cavaliere R., Mondovi B., Moricca G., et al.: Regional perfusion hyperthermia. In Storm F.K. (ed): "Hyperthermia in Cancer Therapy". Boston: G. Hall 369-99, 1983.
7. Wieberdink J., Benckhuijsen C., Braat R.P., et al.: Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur. J. Cancer Clin. Oncol. 18:905-10, 1982.
8. Di Filippo F., Calabro A.M., Giannarelli D., et al.: Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 63:2551-61, 1989.
9. Lee E., Desu M.A.: A computer program for comparing k samples with right-censored data. Comput Methods Programs Biomed. 2:315-21, 1972.
10. Cox D.R.: Regression models and life tables (with discussion) J.R. Stat. Soc. 34:187-220, 1972.
11. Krementz E.T.: Regional perfusion: Current sophistication, what next? Cancer 37:416-32, 1986.
12. Lejeune F.J., De Looft, Ewolenko P., et al.: Objective regression of unexcised melanoma in transit metastases after the hyperthermic isolation perfusion of the limbs with Melphalan. Rec. Res. Cancer Res. 86:276-86, 1983.
13. Storm F.K., Morton D.L.: Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Ann. J. Surg. 150:32-5, 1985.
14. Vaglini M., Ammatuna M., Nava M., et al.: Regional perfusion at high temperature in treatment of Stage IIIA-IIIAB melanoma patients. Tumori 69:585-8, 1983.
15. Hansson J.A., Simert G., Vang J.: The effect of regional perfusion treatment on recurrent melanoma of the extremities. Acta Chir. Scand. 143:33-9, 1977.
16. Rochlin D.B., Smart C.R.: Treatment of malignant melanoma by regional perfusion. Cancer 18:1544-50, 1965.
17. Bulman A.S., Jamieson C.W.: Isolated limb perfusion with Melphalan in the treatment of malignant melanoma. Br. J. Surg. 67:660-2, 1980.
18. Kroon B.B.R.: Regional isolation perfusion in melanoma of the limbs: Accomplishment, unsolved problems, future. Eur. J. Surg. Onc. 14:101-10, 1988.
19. Rosin R.D., Westbury G.: Isolated limb perfusion for malignant melanoma. Practitioner 244:1031-6, 1980.
20. Baas P.C., Schrafford Koops H., Haekstra H.J., et al.: Isolated regional perfusion in the treatment of local recurrence, satellitosis and in transit metastases of melanoma of the extremities. Reg. Cancer Treat. 1:33-6, 1988.
21. Wagner D.E.: A retrospective study of regional perfusion for melanoma. Arch. Surg. 111:410-3, 1976.
22. Stehlin J.S., Giovanella G.C. Gutierrez R.E., et al.: Fifteen years' experience with hyperthermic perfusion for the treatment of soft tissue sarcoma and malignant melanoma of the extremities. Front. Radiat. Ther. Oncol. 18:177-82, 1984.
23. Davis C.D., Ivins J.C., Soule E.G.: Mayo Clinic experience with isolated perfusion for invasive malignant melanoma of the extremities. In "Melanomas: Basic Properties and Clinical Behavior" Vol II. Proceedings of the Ninth International Pigment Cell Conference, Houston, Texas 1975, New York: S. Karger 379, 1976.
24. Aksaz E., Erdem E., Erdem D et al.: TNF-alpha levels in patients with malignant tumors after hyperthermic isolated regional perfusion. J. Exp. Clin. Cancer Res. Dec;21(4):489-93, 2002.
25. Ghussen F., Kruger I., Groth W., et al.: The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 61:654-9, 1988.
26. Briele H.A., Djuric M., Sung D.T., et al.: Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res. 45:1835-89, 1985.
27. Goss P., Parson P.G.: The effect of hyperthermia and Melphalan on survival of human fibroblast strains and melanoma cell lines. Cancer Res 37:152-6, 1977.
28. Reinhold H.S., Hendrich B.: Invited review: tumor microcirculation as a target for hyperthermia. Int. J. Hyperthermia 2:111-37, 1986.
29. Vendetti S., Cicconi R., Piselli P. et al.: Induction and membrane expression of heat shock proteins in heat-treated HPC-4 cells is correlated with increased resistant to LAK-mediated lysis. J. Exp. Clin. Cancer Res. Sep; 19(3):329-34, 2000.